BPI 460372
Alternative Names: BPI-460372Latest Information Update: 28 Dec 2025
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (PO, Tablet)
- 05 Apr 2024 Pharmacodynamics data from a phase I trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacokinetics and adverse events data from a phase I trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)